Nanobiotix Files February 2025 6-K Report

Ticker: NBTX · Form: 6-K · Filed: Feb 12, 2025 · CIK: 1760854

Sentiment: neutral

Topics: sec-filing, 6-K, regulatory-update

TL;DR

Nanobiotix filed its Feb 2025 6-K, confirming 20-F annual report filing.

AI Summary

Nanobiotix S.A. filed a Form 6-K on February 12, 2025, to report its activities for the month of February 2025. The company, a foreign private issuer, is based in Paris, France, and operates in the pharmaceutical preparations sector. This filing indicates they will file their annual report under cover of Form 20-F.

Why It Matters

This filing provides an update on Nanobiotix S.A.'s regulatory reporting status, confirming their adherence to SEC requirements for foreign private issuers.

Risk Assessment

Risk Level: low — This is a routine filing confirming reporting status and does not contain new financial or operational information.

Key Numbers

Key Players & Entities

FAQ

What is the purpose of a Form 6-K filing?

A Form 6-K is a report of foreign private issuers required to be filed with the SEC to provide information that the issuer has made or is required to make public pursuant to the laws of its home country, or that it has filed or is required to file with a stock exchange, or that it has distributed or is required to distribute to its security holders.

What does Nanobiotix S.A. indicate regarding its annual report filing?

Nanobiotix S.A. indicates by check mark that it files or will file annual reports under cover of Form 20-F.

Where is Nanobiotix S.A.'s principal executive office located?

Nanobiotix S.A.'s principal executive office is located at 60 Rue de Wattignies, 75012 Paris, France.

What is the SIC code for Nanobiotix S.A.?

The Standard Industrial Classification (SIC) code for Nanobiotix S.A. is 2834, which corresponds to Pharmaceutical Preparations.

What is the filing date of this Form 6-K?

This Form 6-K was filed on February 12, 2025.

Filing Stats: 172 words · 1 min read · ~1 pages · Grade level 9.1 · Accepted 2025-02-12 16:15:04

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Nanobiotix S.A. (Registrant) Date: February 12, 2025 /s/ Bart Van Rhijn Bart Van Rhijn Chief Financial Officer

View Full Filing

View this 6-K filing on SEC EDGAR

View on Read The Filing